OncoPlexDx
NantOmics is a leader in molecular diagnostic testing and employs an integrated panomic approach to inform personalized treatment options for cancer patients. They analyze both normal and tumor cells from the same patient, following variances from DNA to RNA to protein to drug, utilizing a highly scalable cloud-based infrastructure capable of processing thousands of genomes daily. Their proprietary analytical platform provides comprehensive molecular profiles, actionable intelligence, and decision support at the point of care, aiming to improve cancer outcomes through precision medicine and advanced AI-driven insights.
Industries
Nr. of Employees
small (1-50)
OncoPlexDx
Rockville, Maryland, United States, North America
Products
Comprehensive multi-omic clinical profiling report (integrated DNA, RNA, proteomics)
A clinical laboratory report that integrates paired tumor-normal DNA sequencing, whole-transcriptome profiling, and targeted quantitative proteomics into a consolidated interpretation to inform personalized cancer treatment decisions.
Targeted proteomics assay panels for clinical biomarkers
Multiplexed mass-spectrometry assay panels for quantitative measurement of clinically actionable protein biomarkers from clinical specimens, including archived FFPE tissue.
Liquid biopsy tumor profiling service
Blood-based testing for circulating tumor DNA and cell-free RNA biomarkers to support non-invasive tumor profiling and longitudinal monitoring of treatment response.
AI-enhanced digital pathology analysis package
Software-enabled analysis that applies deep-learning models to whole-slide images for subtype classification and spatial immune mapping, with outputs that can be combined with molecular profiles for research and diagnostic interpretation.
Comprehensive multi-omic clinical profiling report (integrated DNA, RNA, proteomics)
A clinical laboratory report that integrates paired tumor-normal DNA sequencing, whole-transcriptome profiling, and targeted quantitative proteomics into a consolidated interpretation to inform personalized cancer treatment decisions.
Targeted proteomics assay panels for clinical biomarkers
Multiplexed mass-spectrometry assay panels for quantitative measurement of clinically actionable protein biomarkers from clinical specimens, including archived FFPE tissue.
Liquid biopsy tumor profiling service
Blood-based testing for circulating tumor DNA and cell-free RNA biomarkers to support non-invasive tumor profiling and longitudinal monitoring of treatment response.
AI-enhanced digital pathology analysis package
Software-enabled analysis that applies deep-learning models to whole-slide images for subtype classification and spatial immune mapping, with outputs that can be combined with molecular profiles for research and diagnostic interpretation.
Services
Comprehensive clinical molecular profiling (integrated DNA, RNA, proteomics)
Laboratory service that integrates paired tumor-normal DNA sequencing, whole-transcriptome profiling, and targeted quantitative proteomics to produce an integrated molecular report linking alterations and pathway disruptions to potential therapeutic options.
Targeted proteomics and quantitative mass-spectrometry assays
Clinical-grade, multiplexed targeted mass spectrometry assays for quantitation of actionable protein biomarkers from tissue (including FFPE) either as standalone tests or integrated into multi-omic workflows.
Liquid biopsy and longitudinal circulating biomarker analysis
Blood-based molecular testing for ctDNA and cfRNA to support non-invasive tumor profiling, longitudinal monitoring of treatment response, and biomarker discovery.
Digital pathology and AI-driven image analysis
Machine-learning analysis of whole-slide histology images to classify tumor subtypes, map spatial immune infiltration, and generate image features that can be integrated with molecular data for research and diagnostic support.
Neoepitope discovery and support for personalized immunotherapy programs
Computational identification of expressed, HLA-presented neoepitopes from paired tumor-normal and RNA sequencing to support design of individualized vaccines and to provide biomarker readouts for immunotherapy trials.
Comprehensive clinical molecular profiling (integrated DNA, RNA, proteomics)
Laboratory service that integrates paired tumor-normal DNA sequencing, whole-transcriptome profiling, and targeted quantitative proteomics to produce an integrated molecular report linking alterations and pathway disruptions to potential therapeutic options.
Targeted proteomics and quantitative mass-spectrometry assays
Clinical-grade, multiplexed targeted mass spectrometry assays for quantitation of actionable protein biomarkers from tissue (including FFPE) either as standalone tests or integrated into multi-omic workflows.
Liquid biopsy and longitudinal circulating biomarker analysis
Blood-based molecular testing for ctDNA and cfRNA to support non-invasive tumor profiling, longitudinal monitoring of treatment response, and biomarker discovery.
Digital pathology and AI-driven image analysis
Machine-learning analysis of whole-slide histology images to classify tumor subtypes, map spatial immune infiltration, and generate image features that can be integrated with molecular data for research and diagnostic support.
Neoepitope discovery and support for personalized immunotherapy programs
Computational identification of expressed, HLA-presented neoepitopes from paired tumor-normal and RNA sequencing to support design of individualized vaccines and to provide biomarker readouts for immunotherapy trials.
Expertise Areas
- Integrated multi-omics molecular diagnostics
- Tumor-normal genomic analysis with RNA-informed interpretation
- Targeted quantitative proteomics for clinical specimens
- Digital pathology and multi-modal machine learning
Key Technologies
- Tumor-normal whole-genome / whole-exome sequencing
- Whole-transcriptome RNA sequencing (RNA-seq)
- Targeted mass spectrometry (SRM / multiplexed MS)
- Digital pathology with deep learning